PCA3 Molecular Urine Test for Predicting Repeat Prostate Biopsy Outcome in Populations at Risk: Validation in the Placebo Arm of the Dutasteride REDUCE Trial-Reference-Cited by-同舟云学术

PCA3 Molecular Urine Test for Predicting Repeat Prostate Biopsy Outcome in Populations at Risk: Validation in the Placebo Arm of the Dutasteride REDUCE Trial

Published:2010-11 Issue:5 Volume:184 Page:1947-1952
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Aubin Sheila M.J.¹,Reid Jennifer¹,Sarno Mark J.¹,Blase Amy¹,Aussie Jacqueline¹,Rittenhouse Harry¹,Rittmaster Roger²,Andriole Gerald L.³,Groskopf Jack¹

Affiliation:

1. Gen-Probe Incorporated, San Diego, California

2. GlaxoSmithKline Incorporated, Durham, North Carolina

3. Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, Missouri

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference12 articles.

1. DD3: a new prostate-specific gene, highly over-expressed in prostate cancer;Bussemakers;Cancer Res,1999

2. DD3PCA3, a very sensitive and specific marker to detect prostate tumors;De Kok;Cancer Res,2002

3. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer;Hessels;Eur Urol,2003